[DEPDC1 is Highly Expressed in Lung Adenocarcinoma and Promotes Tumor Cell Proliferation]

Lung cancer is the leading cause of death worldwide, and lung adenocarcinoma is the main subtype of lung cancer. DEP domain-containing 1 (DEPDC1) has been proved to be closely related to the occurrence and development of most tumors, and the overexpression of DEPDC1 in lung adenocarcinoma has been preliminarily confirmed. This study aims to explore the relationship between the expression of DEPDC1 and the clinical prognosis of lung adenocarcinoma, and to preliminarily explore the possibility of DEPDC1 as a potential biomarker and therapeutic target of lung adenocarcinoma.

The bioinformatics website GEPIA database was used to collect relevant information, and the prognostic was analyzed online. Patient data were collected for statistical analysis, and immunohistochemical staining was performed on the collected samples. Subsequently, lung adenocarcinoma cells were cultured in vitro, and the knockout efficiency was verified by Western blot and reverse transcription-quantitative polymerase chain reaction (RT-qPCR), and cell proliferation experiments were performed.

The expression of DEPDC1 in lung adenocarcinoma tissues is significantly higher than that in adjacent normal tissues. The high expression of DEPDC1 is correlated with the tumor size and clinical stage of lung adenocarcinoma and knocking down DEPDC1 inhibits the proliferation of A549 and H1975 cells.

DEPDC1 plays an important role in the progression and evolution of lung adenocarcinoma. And it is expected to become an important therapeutic target and a potential new biomarker for lung adenocarcinoma.